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The need for specific care, coupled with new family arrangements, has contributed to the increasing 
institutionalization of elderly members. The purpose of this study was to evaluate drug use by 
institutionalized older adults according to Beers Criteria. This prospective, longitudinal study was 
conducted in the three non-profit long-stay geriatric care institutions of Campo Grande, in the Central-West 
region of Brazil. All subjects aged 60 years and above on November 2011 were included and followed 
until November 2012. Eighteen subjects were excluded and the final sample consisted of 133 individuals 
aged 60 to 113 years. Overall, 212 medications were used at geriatric care institution A, 532 at B, and 
1329 at C. Thirty-four drugs were inappropriately prescribed 89 times at geriatric care institution A 
(41.98%), 49 prescribed 177 times at B (33.27%), and 91 prescribed 461 times at C (34.68%). Statistical 
differences in the inappropriate drug use were found between genders (p=0.007). The most commonly 
used potentially inappropriate medication were first-generation antihistamines (15.34%). There was a 
high frequency in the use of potentially inappropriate medications which can initiate marked side effects 
and may compromise the fragile health of institutionalized elderly. Thus, adopting the Beers Criteria in 
prescribing medication contributes to minimize adverse reactions and drug interactions.
Uniterms: Medicines/inappropriate use. Medicines/prescription. Polypharmacy. Elderly/inappropriate 
use of medicines. Beers Criteria.
A exigência de cuidados específicos, aliada aos novos arranjos familiares, tem contribuído para a crescente 
institucionalização dos idosos. O objetivo do presente trabalho foi avaliar o uso de medicamentos por 
idosos institucionalizados utilizando os Critérios de Beers. Este estudo longitudinal prospectivo foi 
realizado nas três instituições de longa permanência para idosos de Campo Grande, Centro-Oeste do 
Brasil. Todos os sujeitos com 60 anos ou mais foram incluídos em Novembro de 2011 e acompanhados 
até Novembro de 2012. Dezoito idosos foram excluídos, sendo a amostra final composta por 133 sujeitos 
com idade entre 60 e 113 anos. O total de medicamentos utilizados foi 212 na instituição A, 532 na B 
e 1329 na C. Foram identificados 34 medicamentos inapropriados, prescritos 89 vezes na instituição A 
(41.98%), 49 prescritos 177 vezes na B (67.29%) e 90 prescritos 460 vezes na C (34.61%). Este estudo 
demonstrou diferença estatística na utilização de medicamentos inapropriados entre os gêneros (p=0.007). 
Os anti-histamínicos de 1ª geração foram os medicamentos potencialmente inapropriados para idosos 
mais utilizados (15.34%). Houve elevada frequência no uso de MPI, os quais podem desencadear efeitos 
colaterais acentuados e comprometer mais a saúde fragilizada do idoso institucionalizado. Ainda, a 
adoção dos Critérios de Beers na prescrição contribui para minimizar as reações adversas e interações 
medicamentosas.
Unitermos: Medicamentos/uso inapropriado. Medicamentos/prescrição. Politerapia. Idoso/uso 
inapropriado de medicamentos. Critério de Beers.
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INTRODUCTION
Older adults have unique medication requirements as 
organ functions are reduced by age-related physiological 
changes. These changes affect the pharmacokinetics and 
pharmacodynamics of drugs, making it difficult to draw a 
clear-cut line between risks and benefits of their use in this 
population (Mangoni, Jackson, 2003; Baldoni et al., 2010).
Drugs absorption may be impaired in elderly patients 
due to increasing gastric pH. This increase enhances the 
absorption of alkali drugs and reduces the absorption of 
acidic drugs. Aging also promotes reduced surface intestinal 
absorption and lower esophageal sphincter pressure and 
peristalsis (Baldoni et al., 2010; Ferreira, 2010).
With increasing age, the amount of water in the body 
decreases, adipose mass increases and lean mass decreases. 
Thus distribution volume is less for water soluble drugs and 
greater for liposoluble drugs. Consequently, liposoluble 
drugs tend to accumulate in adipose tissue, increasing 
their plasma half-life and period of action, and the risk of 
adverse effects. Reduced distribution volume for water-
soluble may increase their initial concentration in the central 
compartment, resulting in higher plasma concentrations 
(Baldoni et al., 2010). Biotransformation can be affected by 
hepatic blood flow, which can be reduced by as much as half 
in the elderly. This results in reduced first pass metabolism 
and increased bioavailability of drugs (Mangoni, Jackson, 
2003). There is a decrease in the activity of cytochrome 
P450 enzymes. Thus, some medications may continue to 
exert their effects for a longer than expected (Nobrega, 
Karnikowski, 2005). One example is diazepam, which has 
a half-life of 24 hours in younger patients and 90 hours in 
elderly patients (Mangoni, Jackson, 2003).
Renal function is an important parameter for 
the clearance of pharmaceutical agents, in the elderly; 
this function progressively declines with advancing 
age. Reduced renal blood flow, tubular clearance, and 
creatinine clearance and increase serum creatinine, result 
in two clinically significant effects - increased half-life and 
serum levels of drugs (Ferreira, 2010).
For drugs with a narrow therapeutic safety margin, 
such as digoxin, aminoglycosides and warfarin, serious 
side effects may occur in elderly patients if a dosage 
adjustment is not based on creatinine clearance value 
(Mangoni, Jackson, 2003; Baldoni et al., 2010).
In relation to pharmacodynamics, modifications in 
the number of drugs, receptor affinity to drugs, and signal 
transduction, especially for agents that depress the central 
nervous system such as opioid analgesics, hypnotics and 
sedatives cause increased sensitivity to these triggered 
effects (Hutchison, O’Brien, 2007; Ferreira, 2010).
The need for specific care, coupled with new 
family arrangements, has contributed to increasing 
institutionalization of elderly family members. 
Institutionalized older adults differ from those who live 
with their families as they present specific characteristics 
such great frailty, impaired functionality, and physical, 
psychological and social dependence (Gorzoni, Pires, 
2006). Comorbidities and chronic degenerative diseases 
make the elderly prone to using concomitant medications, 
increasing the risk of adverse events occurrence (Rajska-
Neumann et al., 2011; Liu et al., 2012).
The 2000 Population Census of Brazil produced 
by the Brazilian Institute of Geography and Statistics 
(Instituto Brasileiro de Geografia e Estatistica - IBGE) 
revealed less than 100,000 senior citizens living in 
collective households, this represents less than 1% of 
the elderly population. Approximately 10 years later, a 
survey conducted by the Institute for Applied Economic 
Research (Instituto de Pesquisa Econômica Aplicada - 
IPEA) identified 3548 long-stay geriatric care institutions 
in Brazil, where 83,870 seniors citizens were living, 0.5% 
of the elderly population (IPEA, 2011).
The need for caution in prescribing drugs to older 
adults has led to the development of a number of tools to 
assist this practice. One of these resources is the Beers 
Criteria of potentially inappropriate medications (PIM) 
use in older adults, developed by Beers et al. (1991). 
These criteria were established to reduce the risks of 
iatrogenesis and adverse reactions. In 1997, the criteria 
were updated by Beers to include degrees of frailty. In 
2003, Fick et al. reviewed the original guidelines and 
published the latest update in the following decade (Fick 
et al., 2012). Potentially inappropriate medications 
(PIM) are medications or classes of medications that 
should be avoided in elderly patients of 60 or more 
years. Medications are placed in this category when they 
have no evidence-based indication, do not present cost-
effectiveness, or there are safer alternatives (Varallo, 
Capucho, Planeta, 2011; Beers et al., 1991).
In this context, several different instruments can 
be employed; these include the French list (Laroche, 
Charmes, Merle, 2007), the Medication Appropriateness 
Index (Hanlon et al., 1992), the STOPP/START criteria 
(Gallagher et al., 2008), the PRISCUS list (Holt, 
Schmield, Petra, 2010), the Korean list (Kim, Heo, Lee, 
2010), IPET (Naugler et al., 2000) and Beers Criteria 
(Beers et al., 1991; Beers, 1997; Fick et al., 2003; Fick et 
al., 2012). The Beers Criteria is the most commonly used 
by researchers worldwide (Gorzoni, Fabbri, Pires, 2008; 
Ribeiro et al., 2005).
Many of the studies on medication use in the 
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elderly focus on inpatients, outpatients or those living in 
the community (Flores, Mengue, 2005; Winit-Watjana, 
Sakulrat, Kespichayawattana, 2008; Lin et al., 2011; 
Rajska-Neumann et al., 2011; Varallo et al., 2011; Liu et 
al., 2012; Pinto, Ferre, Pinheiro, 2012), while research on 
drug use by elderly institutionalized adults is still scarce 
(Correr et al.,2007; Aguiar et al., 2008; O’Mahony et al., 
2010; Fochat et al., 2012).
The purpose of this study was to identify and 
quantify drug use in elderly institutionalized adults using 
the Beers Criteria (2012).
METHODS
Study design and setting
This prospective, longitudinal study was conducted 
in the three non-profit long-stay geriatric care institutions 
(herein designated A, B, and C) of Campo Grande in 
the Central-West region of Brazil. Non-profit long-stay 
geriatric care institutions are residential nursing homes 
for individuals of 60 years and over who have some 
degree of difficulty in performing daily activities and 
for those whose families lack the financial, physical, or 
emotional resources to provide them with the necessary 
care (ANVISA, 2005).
Study population
Subjects aged 60 years and over (Brasil, 2003) living 
at one of the non-profit long-stay geriatric care institutions 
of Campo Grande, Brazil, in November 2011 were 
included in the study and followed until November 2012.
Those institutionalized after November 2011 were 
excluded, as were those who died or were discharged from 
the institutions during the study period.
Data collection 
Data was collected weekly from the subjects’ 
medical records; the variables investigated were gender, 
age, number of prescribed drugs and identification of 
their active principles, and PIM occurrence according 
to the Beers Criteria (Fick et al., 2012), (a) potentially 
inappropriate medications for use in older adults 
independent of diagnoses or conditions, (b) potentially 
inappropriate medications for use in older adults 
considering diagnoses and conditions, and (c) medications 
that, although potentially inappropriate to older adults, can 
be used with caution.
Quantification of the total number of used drugs 
and evaluation of their unsuitability took into account the 
number of times the same drug was prescribed, so as to 
identify repeated exposure to PIM.
Data treatment and interpretation
Data were expressed as absolute and relative 
frequencies, means and standard deviations. Statistical 
analyses were performed using Epi Info software, version 
3.5.1, 2008 (CDC, 2009) and BioEstat, version 5.0 
(Ayres et al., 2007). Associations between variables were 
compared using Pearson’s Chi-squared test and prevalence 
ratio with 95% confidence interval (CI).
Ethical issues
The study was approved by the Federal University of 
Mato Grosso do Sul Research Ethics Committee (protocol 
number 2212/2011).
Healthcare professionals responsible for the subjects 
proposed their treatment and the study evaluations did not 
interfere with this process.
RESULTS
Table I shows the profile of the study population. 
During data collection, 18 subjects were excluded (16 
died and two left the institutional setting). The final sample 
thus consisted of 133 individuals aged 60 to 113 years. 
Mean ages (by institution) were 77.94±7.94 years (A), 
76.17±11.10 (B), and 78.49±10.15 (C).
Overall, 212 medications (with 91 active principles) 
were used at A, 532 (with 134) at B, and 1329 (with 265 
active principles) at C. Mean numbers of active principles 
per individual were 12.47 ± 5:51 (A), 17.73 ± 8.9 (B), and 
15.45 ± 9.63 (C).
Thirty-four drugs were inappropriately prescribed 
89 times at A (41.98%), 49 prescribed used 177 times at 
B (33.27%), and 91 prescribed 461 times at C (34.68%). 
In all, roughly 35% of the drugs prescribed were classified 
as PIM and statistical differences were found between 
genders for inappropriate use of drugs (Pearson’s Chi-
squared test, P = 0.007) (Table II).
All subjects living at geriatric care institutions were 
treated with PIM, except one (1.33%) older adult from 
institution C, who did not use any medicine.
Table III lists the PIM used at the geriatric care 
institutions; the most commonly used were first-
generation antihistamines (54/15.34%), non-steroidal 
anti-inflammatories (49/13.92%), and antipsychotics 
(49/13.92 %).
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TABLE II – Potentially inappropriate medication for the elderly
Variables
Medication use
Total
P RR(95% CI)Inappropriate Appropriate
N % n % N %
Institution
A 89 41.98 123 58.02 212 10.23 0.07 1
B 177 33.27 355 66.73 532 25.66 1.45 (1.25-1.69)
C 461 34.69 868 65.31 1329 64.11 1.36 (1.20-1.55)
Total 727 35.07 1346 64.93 2073 100.00 - -
Gender
Male 415 37.76 684 62.24 1099 53.01 0.007 1
Female 312 32.03 662 63.86 974 46.99 1.29 (1.16-1.42)
Total 727 35.07 1346 64.93 2073 100.00
RR: Relative Risk; CI: Confidence Interval.
TABLE I – Characteristics of the study population
Variable
Long-stay geriatric care institution
A B C Total
M 
n (%)
F 
n (%)
M 
n (%)
F 
n (%)
M 
n (%)
F 
n (%)
M 
n (%)
F 
n (%)
Initial number of subjects 11 (55.00) 9 (45.00) 21 (58.33) 15 (41.67) 52 (54.73) 43 (45.27) 84 (55.63) 67 (44.37)
Deaths 1 (5.00) 1 (5.00) 3 (8.33) 2 (5.55) 2 (2.10) 7 (7.36) 6 (3.97) 10 (6.62)
Discharge from 
institutional setting
0 (0.00) 1 (5.00) 1 (2.78) 0 (0.00) 0 (0.00) 0 (0.00) 1 (0.66) 1 (0.66)
Number of subjects in 
the sample
10 (58.82) 7 (41.18) 17 (56.67) 13 (43.33) 50 (58.14) 36 (41.86) 77 (57.89) 56 (42.10)
Age range (years)
 60-69 2 (11.76) 0 (0.00) 5 (16.67) 3 (10.00) 15 (17.44) 4 (4.65) 22 (16.54) 7 (5.26)
 70-79 6 (35.29) 2 (11.76) 7 (23.33) 6 (20.00) 13 (15.12) 13 (15.12) 26 (19.55) 21 (15.79)
 80-89 2 (11.76) 4 (23.53) 2 (6.67) 3 (10.00) 19 (22.09) 11 (12.79) 23 (17.29) 18 (13.53)
 90-99 0 (0.00) 1 (5.88) 2 (6.67) 0 (0.00) 2 (2.32) 7 (8.14) 4 (3.01) 8 (6.01)
Over 100 0 (0.00) 0 (0.00) 1 (3.33) 1 (3.33) 1 (1.16) 1 (1.16) 2 (1.50) 2 (1.50)
Number of drugs 
prescribed per subject
115 97 263 269 714 615 1092 981
M: Male; F: Female
Those with less than 10% use were barbiturates at A 
(1/2.38%) and C (7/3.13%); levothyroxine at A (2/4.76%) 
and C (5/2.23%); oral mineral oil at institution B (1/1.16%) 
and C (6/2.67%); antiarrhythmics at institutions B 
(1/0.45%) and C (5/1.79%); spironolactone at B (2/2.32%) 
and C (4/1.78%); the antithrombotic ticlopidine (1/0.45%), 
central alpha-adrenergic agonists (5/1.79%), non-
benzodiazepine hypnotics (1/0.45%), and Ergot mesylates 
(3/1.34%) at institution C; at all facilities, metoclopramide 
(1/2.38%, 1/1.16%, 7/3.12%, respectively at A, B and C) 
and muscle relaxants at A (1/2.38%), B (3/3.48%) and C 
(5/1.79%).
Table IV presents data on PIM use in older 
adults considering diagnoses or conditions. Potential 
interactions were also observed for PIM use on fewer 
than 10 occasions: cyclo-oxygenase 2 inhibitors at A 
(1/1.30%), B (2/1.49%) and C (6/1.80%) and diltiazem 
at C (1/0.30%), a calcium channel blocker, which is 
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potentially inappropriate for older adults with heart 
failure and chronic constipation.
Interactions involving pioglitazone with heart failure 
were seen at A (1/1/30%) and antipsychotic olanzapine 
and thioridazine at C (4/1.20%) with syncope, convulsion, 
delirium, dementia, falls/fractures, chronic constipation, 
benign prostatic hyperplasia, and Parkinson’s disease. 
Muscle relaxants carisoprodol and cyclobenzaprine 
used at A (1/1.30%), B (3/2.24%) and C (5/1.50%) and 
oxybutynin, used for urinary incontinence at C (2/0.60% 
) should be used by older adults with delirium, dementia, 
chronic constipation, benign prostatic hyperplasia, or 
by those who suffered falls or fractures. Interactions 
involving hypnotics and sedatives with delirium were 
seen at A (1/1.30%) and C (7/2.10%); non-benzodiazepine 
hypnotics (zopiclone) and older adults with history of falls 
or fractures seen at C (1/0.30%), and with caffeine seen 
at A (1/1.30%) and B (1/0.75%) should also be avoided.
Figure 1 shows the results for PIM that can be 
used with caution. Antiplatelet agents (75/37.88%), 
antidepressants (56/28.28%), and antipsychotics 
(49/24.74%) predominated.
Antipsychotics: haloperidol, olanzapine, risperidone, 
thioridazine. Serotonin-noradrenaline reuptake–inhibiting 
antidepressants: duloxetine, venlafaxine. Selective 
serotonin reuptake–inhibiting antidepressants: citalopram, 
escitalopram, fluoxetine, paroxetine, sertraline. 
Vasodilators: dihydroergocristinemesylate, co-dergocrin, 
isosorbide, sildenafil, pentoxifylline, propatylnitrate.
DISCUSSION
Our results reveal the existence of risks related 
to medication use by institutionalized older adults in 
the three non-profit long-stay geriatric care institutions 
investigated. By providing a broad overview of PIM use by 
institutionalized older adults, this investigation encourages 
the development of mechanisms to evaluate risk-
minimizing processes, so as to increase the likelihood of 
positive therapeutic outcomes for the geriatric population.
All used drugs were considered independent of 
formulation type or administration route, since the Beers 
Criteria (Fick et al., 2012) does not discriminate between 
these parameters. The male predominance in the surveyed 
institutions contrasts with the greater life expectancy 
pattern seen in women in Brazil (IBGE, 2011) and in other 
studies on institutionalized older adults (Aguiar et al., 
2008; Fochat et al., 2012). However Correr et al. (2007) 
found elderly males in the majority thus corroborating our 
finding. Our study also revealed greater use of PIM by 
males, but interpretation of this finding should take into 
account that drugs such as doxazosin (an alpha-blockers) 
TABLE III – Classification of potentially inappropriate medication for the elderly
Pharmacological class/drugs
Long-stay geriatric care institutions
A (n = 87) B (n = 177) C (n = 461) Total (n = 725)
M F M F M F M F
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
First-generation antihistamines 4 (9.52) 6 (14.28) 3 (3.49) 4 (4.65) 24 (10.71) 13 (5.80) 31 (8.81) 23 (6.53)
Antispasmodics 0 (0.00) 2 (4.76) 0 (0.00) 4 (4.65) 6 (2.68) 5 (2.23) 6 (1.70) 11 (3.12)
Anti-infective agents 1 (2.38) 1 (2.38) 0 (0.00) 3 (3.49) 3 (1.34) 2 (0.89) 4 (1.14) 6 (1.70)
Alpha-blockers 0 (0.00) 0 (0.00) 9 (10.46) 0 (0.00) 9 (4.02) 0 (0.00) 18 (5.11) 0 (0.00)
Digoxin (>0.125 mg/day) 0 (0.00) 0 (0.00) 2 (2.32) 0 (0.00) 6 (2.68) 3 (1.34) 8 (2.27) 3 (0.85)
Immediate-release nifedipine 0 (0.00) 0 (0.00) 5 (5.81) 1 (1.16) 3 (1.34) 1 (0.45) 8 (2.27) 2 (0.57)
Tertiary tricyclic antidepressants 5 (11.90) 3 (7.14) 7 (8.14) 5 (5.81) 1 (0.45) 5 (2.23) 13 (3.69) 13 (3.69)
Antipsychotics 1 (2.38) 1 (2.38) 4 (4.65) 4 (4.65) 21 (9.37) 18 (8.03) 26 (7.39) 23 (6.53)
Benzodiazepines 0 (0.00) 4 (9.52) 6 (6.98) 4 (4.65) 9 (4.02) 7 (3.12) 15 (4.26) 15 (4.26)
Insulin 0 (0.00) 0 (0.00) 3 (3.49) 0 (0.00) 8 (3.57) 6 (2.68) 11 (3.12) 6 (1.70)
Oral non-selective COX-inhibiting 
NSAIDs
1 (2.38) 8 (19.05) 6 (6.98) 8 (9.30) 18 (8.03) 8 (3.57) 25 (7.10) 24 (6.82) 
Note: First-generation antihistamines: dexchlorpheniramine, cyproheptadine, promethazine, hydroxyzine, chlorpheniramine. Antispasmodics: 
hyoscine, scopolamine. Anti-infective agents: nitrofurantoin. Alpha-blockers: doxazosin. Tertiarytricyclic antidepressants, alone or in combination: 
amitriptyline, clomipramine, imipramine. Antipsychotics: haloperidol, olanzapine, risperidone, thioridazine. Short- and intermediate-acting 
benzodiazepines: alprazolam, lorazepam. Long-acting benzodiazepines: clonazepam, diazepam. Oral non-selective COX-inhibiting NSAIDs: 
ketoprofen, diclofenac, ibuprofen, meloxicam. M: Male; F: Female
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- for benign prostatic hyperplasia - are restricted to male 
patients.
PIM use in our study was higher than seen by other 
investigators in Brazil. This may be because the study was 
longitudinal and used the updated Beers Criteria, which 
includes a larger number of PIM. Correr et al. (2007) 
and Aguiar et al. (2008) found 13.5% and 28.7% rates of 
PIM use, respectively. In Ireland, O’Mahony et al. (2010) 
described PIM prescription at 60% in long-stay geriatric 
care institutions.
Only one subject did not use PIM. This is a worrying 
finding, given the often compromised pharmacokinetic 
and pharmacodynamic profile of elderly individuals, 
which can compound the adverse effects of PIM. On the 
other hand, potentially inappropriate medication can be 
used in situations where the benefits outweigh the risks. 
Lin et al. (2011), applying the Beers Criteria during 
an investigation of a rural community in Taiwan found 
that one third of elderly subjects had been prescribed at 
least one PIM (Fick et al., 2003). On the same island, Liu 
TABLE IV – Potentially inappropriate medication for the elderly by reason of drug–disease or drug–syndrome interactions capable 
of worsening the disease or syndrome
Pharmacological classification X drug–
disease / drug–syndrome interaction
Long-stay geriatric care institution
A (n = 77) B (n = 134) C (n = 333) Total (n = 540)
M F M F M F M F
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
NSAID X heart failure; gastric/duodenal 
ulcer; chronic renal disease 
1 (1.30) 8 (10.40) 6 (4.48) 10 (7.46) 18 (5.40) 9 (2.70) 25 (4.63) 27 (5.00)
Corticosteroid X delirium 6 (7.79) 4 (5.19) 10 (7.46) 13 (9.70) 44 (13.21) 32 (9.61) 60 (11.11) 49 (9.07)
Cilostazol X heart failure 2 (2.60) 1 (1.30) 5 (3.73) 3 (2.24) 11 (3.30) 6 (1.80) 18 (3.33) 10 (1.85)
Peripheral alpha blocker X syncope; 
urinary incontinence
0 (0.00) 0 (0.00) 9 (6.72) 0 (0.00) 9 (2.70) 0 (0.00) 18 (3.33) 0 (0.00)
Tricyclic antidepressants X syncope; 
chronic constipation; fractures; delirium; 
dementia; benign prostatic hyperplasia
5 (6.49) 3 (3.90) 7 (5.22) 5 (3.73) 2 (0.60) 6 (1.80) 14 (2.59) 14 (2.59)
Selective serotonin reuptake inhibitor X 
fractures
8 (10.39) 4 (5.19) 9 (6.72) 2 (1.49) 15 (4.50) 21 (6.31) 32 (5.92) 27 (5.00)
Haloperidol; risperidone X dementia 
and cognitive impairment; fractures; 
Parkinson’s disease
1 (1.30) 1 (1.30) 4 (2.98) 4 (2.98) 19 (5.70) 16 (4.80) 24 (4.44) 21 (3.89)
Antihistamine (alone or in a combination 
of drugs) X delirium; dementia; fractures; 
chronic constipation; benign prostatic 
hyperplasia
4 (5.19) 6 (7.79) 3 (2.24) 4 (2.98) 28 (8.41) 14 (4.20) 35 (6.48) 24 (3.89)
Antispasmodic X delirium; dementia; 
fractures; chronic constipation; benign 
prostatic hyperplasia
0 (0.00) 1 (1.30) 0 (0.00) 4 (2.98) 6 (1.80) 5 (1.50) 6 (1.11) 10 (1.85)
Benzodiazepine X delirium; dementia; 
fractures
0 (0.00) 4 (5.19) 6 (4.48) 4 (2.98) 9 (2.70) 7 (2.10) 15 (2.78) 15 (2.78)
H2-receptor antagonist X delirium; 
dementia
7 (9.09) 1 (1.30) 10 (7.46) 5 (3.73) 9 (2.70) 7 (2.10) 26 (4.81) 13 (2.41)
Antiemetic X Parkinson’s disease 3 (3.90) 2 (2.60) 3 (2.24) 2 (1.49) 9 (2.70) 5 (1.50) 15 (2.78) 9 (1.67) 
NSAIDs: ketoprofen, ketorolac, diclofenac, ibuprofen, meloxicam. Corticosteroids: beclomethasone, betamethasone, budesonide, desonide, 
dexamethasone, fludrocortisone, fludroxycortide, hydrocortisone, prednisone, prednisolone, triamcinolone. Peripheral alpha-blockers: 
doxazosin. Tertiary tricyclic antidepressants: amitriptyline, clomipramine, imipramine, nortriptyline. Selective serotonin reuptake inhibitors: 
citalopram, escitalopram, fluoxetine, sertraline, paroxetine. Antihistamines: dexchlorpheniramine, cyproheptadine, promethazine, hydroxyzine, 
chlorpheniramine, dimenhydrinate, loratadine, meclizine. Antispasmodics: scopolamine and hyoscine. Benzodiazepines: alprazolam, lorazepam, 
flunitrazepam, bromazepam, nitrazepam, clonazepam, diazepam. H2-receptor antagonists: ranitidine. Antiemetics: metoclopramide, promethazine. 
M: Male; F: Female
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et al. (2012) found that 36.2% of elderly patients had been 
prescribed at least one PIM when using STOPP (Screening 
Tool of Older Persons’ Potentially Inappropriate 
Prescriptions) criteria, a resource developed in Ireland for 
PIM evaluation (Gallagher et al., 2008).
The high number of prescriptions for first-
generation anti-histamines, tricyclic antidepressants, 
and antipsychotics found at the geriatric care institutions 
investigated raises concerns. Caution is required 
in prescribing these agents, irrespective of patient 
clinical condition, as these drugs have a pronounced 
anticholinergic effect, progressively reduced clearance 
with advancing age, and increased tolerance when used as 
hypnotics. They can also increase the risks of confusion, 
dry mouth, constipation, blurred vision, urinary retention, 
and tachycardia (DiPiro et al., 2011).
Drugs with pronounced anticholinergic effects are 
also categorized as PIM for older adults due to drug–
disease or drug-syndrome interactions stemming from 
increased tissue responsiveness and central cholinergic 
hypofunction and dysfunction in old age and dementia 
(Bartus, 2000). Kim, Heo, Lee (2010) confirmed these 
effects while compiling a list of potentially inappropriate 
medications for elderly Koreans, with the aid of the Delphi 
method (Ablah et al., 2013).
First- and second-generation antipsychotics increase 
the risks of stroke and cardiac QT-interval prolongation 
by altering the electrical properties of cardiac cells and 
causing hypotension (Risch, Groom, Janowsky, 1982). 
They can also trigger symptoms of Parkinson’s by 
antagonizing dopamine receptors (Holt, Schmiedl, Petra, 
2010). In this category, olanzapine and thioridazine should 
not be prescribed to patients with seizures, as these drugs 
reduce the neuronal excitability threshold (Muench, 
Hamer, 2010), they are PIM that can be prescribed with 
caution, owing to their potential to trigger or exacerbate 
the syndrome of inappropriate antidiuretic hormone 
secretion and hyponatremia, requiring that sodium 
levels be monitored when initiating the drug regime or 
changing doses. Monitoring is also necessary with the use 
of carbamazepine, mirtazapine, serotonin-noradrenaline 
reuptake–inhibiting antidepressants, and selective 
serotonin reuptake inhibitors (Fick et al., 2012).
Metoclopramide, an antiemetic and prokinetic drug 
with antidopaminergic action, can cause extrapyramidal 
side effects, including tardive dyskinesia and Parkinsonian 
symptoms, which contraindicate its use unless indicated 
for gastroparesis (Kim, Heo, Lee, 2010).
Non-steroidal anti-inflammatory drugs (NSAID) 
were also prescribed, despite their enhanced side effects in 
elderly patients, which include gastrointestinal bleeding, 
ulcer induction, kidney failure, high blood pressure, and 
cardiovascular changes. Because NSAID promote fluid 
retention and exacerbate heart failure by decreasing 
prostaglandin production, they must not be prescribed to 
patients with heart failure (Sostres, Gargallo, Lanas, 2009).
Steroidal anti-inflammatories and H2-receptor 
antagonists are potentially inappropriate due to drug–
disease interaction (Fick et al., 2012). Steroidal anti-
inflammatories suppress the hypothalamic-pituitary-
adrenal axis and H2-receptor antagonists act on the central 
nervous system (Kenna et al., 2011).
Among drugs for blood pressure control, alpha-
blockers can increase the risks of syncope related to 
bradycardia and orthostatic hypotension. Methyldopa, 
a central-acting alpha agonist antihypertensive that 
decreases sympathetic discharge, is inappropriate given 
its potential to exacerbate depression (Kim, Heo, Lee, 
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FIGURE 1 – Classification of potentially inappropriate medication to be used with caution in older adults.
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2010). Immediate-release nifedipine, a calcium-channel 
blocker, induces hypotension and vasodilatation, lowers 
systemic vascular resistance, and compromises O2 demand 
by myocardial cells (Kowey et al., 2000; Kim, Heo, 
Lee, 2010). Direct vasodilators can exacerbate syncope 
episodes in patients with a history of this condition, and 
should therefore be used with caution (Kim, Heo, Lee, 
2010; Fick et al., 2012).
Among antiarrhythmics categorized as PIM, 
amiodarone is associated with toxicity, thyroid disorders, 
and cardiac QT prolongation and should therefore be 
avoided as first-line treatment for atrial fibrillation. 
Diltiazem can exacerbate heart failure by promoting urinary 
retention (Kowey et al., 2000; Gallagher et al., 2008).
The use of digoxin at doses higher than 0.125 mg/day 
for heart failure is not associated with additional benefits 
and may increase the risk of toxicity, as renal clearance is 
slower in the elderly and this drug has a low therapeutic 
index (Winit-Watjana, Sakulrat, Kespichayawattana, 
2008; Mangoni, Jackson, 2003; Baldoni et al., 2010; Pinto, 
Ferre, Pinheiro, 2012).
Restrictions are also placed on hypnotics and 
sedatives, particularly barbiturates, given the high rates 
of physical dependence, tolerance to sleep benefits, and 
risk of toxicity even at low doses (Holt, Schmiedl, Petra, 
2010; Fick et al., 2012).
Older adults develop increased sensitivity to 
benzodiazepines, owing to slower metabolism and 
biotransformation difficulties, which elevate the risks 
of cognitive impairment, delirium, falls, fractures, and 
accidents (Baldoni et al., 2010). The Beers Criteria 
(Fick et al., 2012) categorize benzodiazepines as 
short-, intermediate-, and long-acting, and lists the 
following active principles: alprazolam, estazolam, 
lorazepam, oxazepam, temazepam, triazolam, clorazepate, 
chlordiazepoxide, chlordiazepoxide-amitriptyline, 
clonazepam, diazepam, flurazepam, and quazepam.
In Brazil ,  f lunitrazepam, ni trazepam, and 
bromazepam are prescribed and were included in this 
investigation. These drugs were not considered by the 
Beers Criteria because there is no record of them at the 
Food and Drug Administration (FDA, 2013).
The non-benzodiazepine hypnotic eszopiclone, 
indicated for treatment of insomnia, is categorized as a 
PIM by the Beers Criteria, regardless of patient clinical 
condition. Zopiclone, a chiral drug used in racemic form 
and exhibiting pharmacological activity related to the 
eszopiclone enantiomer (Zuo et al., 2013), is also classified 
as a PIM and should be avoided for chronic use because of 
its agonistic properties toward benzodiazepine receptors and 
side effects similar to these (Holt, Schmiedl, Petra, 2010).
No evidence of effectiveness has been found for 
Ergot mesylates, prescribed for headaches, memory 
impairment, cerebrovascular disease, and peripheral 
vascular disorders (Holt, Schmiedl, Petra, 2010).
Mineral oil by oral route should be avoided, since it 
reduces the cough reflex and increases the risk of aspiration 
and lipid pneumonia (Albuquerque Filho, 2006).
Pioglitazone (an antidiabetic agent) and cilostazol 
(a vasodilator) are considered potentially inappropriate 
medication for the elderly by reason of drug–disease 
or drug–syndrome interactions capable of worsening 
the disease or syndrome in patients with heart failure 
by exacerbating this condition while promoting urinary 
retention (Fick et al., 2012).
PIM to be prescribed with caution include aspirin, 
used for primary prevention of cardiac events—despite 
a lack of evidence of benefits over risks in individuals 
aged 80 years and older, requires monitoring to prevent 
hemorrhagic events (Gallagher et al., 2008).
We concluded that there was a high frequency of 
potentially inappropriate medication use which can initiate 
marked side effects such as hypotension, constipation, 
extrapyramidal effects, sedation, weakness, renal failure, 
sleep disorders and can compromise the fragile health of 
institutionalized elderly individuals. Therefore adopting 
the Beers Criteria in prescribing could contribute to 
minimize adverse reactions and drug interactions.
Awareness is required by all healthcare professionals 
with regard to changes experienced in old age. Drug 
prescription should address changes in pharmacokinetics 
and pharmacodynamics taking place during the aging 
process, so as not to compromise the health status of 
elderly individuals by inappropriate prescription. To 
improve care therapy in the elderly, safer alternatives 
should be sought within the same therapeutic class, there 
should be greater disclosure of lists like this between 
prescribers; and PIM lists or evaluation tools should be 
developed, which are appropriate to Brazil.
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